Categories Earnings, Health Care

Moderna reports higher earnings, wider loss in Q3

Moderna Inc (NASDAQ: MRNA) reported third-quarter 2020 financial results before the opening bell on Thursday. The frontrunner in COVID vaccine research reported Q3 revenue of $157.9 million, which was well above the Wall Street consensus. Meanwhile, net loss widened to $0.59 per share, missing the target that analysts had projected.

On the research front, the company announced that its COVID-19 vaccine candidate (mRNA-1273) is now fully enrolled with 30,000 participants. Moderna currently has four programs in Phase 2 studies, in addition to the Phase 3 study of COVID-19 vaccine.

Moderna inc Q3 2020.

Looking forward to listening to management/ analyst comments on Q3 results? Stay tuned here for Moderna Q3 2020 earnings call transcript

MRNA shares gained 3.2% immediately following the announcement. The stock has more than tripled since the beginning of this year.

For 2020, the company said it now expects a positive cash flow in the range of $0.1 billion to $0.3 billion, driven by customer deposits.

CEO Stéphane Bancel said, “We are actively preparing for the launch of mRNA-1273 and we have signed a number of supply agreements with governments around the world. I believe that if we launch our COVID-19 vaccine, 2021 could be the most important inflection year in Moderna’s history.” 


Most Popular

GameStop (GME) Earnings: Q1 loss narrows on 25% sales growth

Video game retailer GameStop Corp. (NYSE: GME), which has become the talk of the town after the unprecedented stock rally in recent weeks, reported a narrower loss for the first

Should you invest in Steel Dynamics (STLD) stock after 78% rally?

The steel industry managed to shrug off the pandemic blues earlier than expected as the recovery in industrial activity pushed up demand. With the vaccination drive and the government’s aggressive

Campbell Soup (CPB) Q3 Earnings: Key financials and quarterly highlights

Campbell Soup Company (NYSE: CPB) reported third-quarter 2021 earnings results today. Net sales decreased 11% year-over-year to $1.98 billion, as a result of lapping the demand surge at the onset

Add Comment
Viewing Highlight